16914871|t|Studies on the first described Alzheimer's disease amyloid beta mutant, the Dutch variant.
16914871|a|Amyloid protein deposited in cerebral vessel walls and diffuse plaques of patients with hereditary cerebral hemorrhage with amyloidosis, Dutch type (HCHWA-D), is similar to the 40-42 residues amyloid beta (Abeta) in vessel walls and senile plaques in brains of patients with Alzheimer's disease (AD), Down's syndrome, and familial and sporadic cerebral amyloid angiopathy (CAA). In 1990 we sequenced the amyloid beta-protein precursor (AbetaPP) gene from HCHWA-D patients revealing a single mutation that results in an amino acid substitution, Abeta E22Q. Subsequent identification of additional mutations in the AbetaPP gene in familial AD (FAD) pedigrees revealed that whereas substitutions in the middle of Abeta, residues Abeta21-23, are predominantly vasculotropic, those found amino- or carboxyl-terminal to the Abeta sequence within AbetaPP enhance amyloid parenchymal plaque deposition. Studies of transfected cells showed that substitutions amino- or carboxyl-terminal to Abeta lead to either greater Abeta production or to enhanced secretion of the more hydrophobic thus more fibrillogenic Abeta1-42. Substitutions in the center of Abeta facilitate rapid aggregation and fibrillization, slower clearance across the blood-brain barrier and perivascular drainage to the systemic circulation, possibly higher resistance to proteolysis, and enhanced toxicity towards endothelial and smooth muscle cells. However, most AD patients have no genetic defects in AbetaPP, indicating that other factors may alter Abeta production, conformation, and/or clearance initiating the disease process.
16914871	31	50	Alzheimer's disease	Disease	MESH:D000544
16914871	51	63	amyloid beta	Gene	351
16914871	165	173	patients	Species	9606
16914871	179	226	hereditary cerebral hemorrhage with amyloidosis	Disease	MESH:D028243
16914871	283	295	amyloid beta	Gene	351
16914871	297	302	Abeta	Gene	351
16914871	324	338	senile plaques	Disease	MESH:D058225
16914871	352	360	patients	Species	9606
16914871	366	385	Alzheimer's disease	Disease	MESH:D000544
16914871	387	389	AD	Disease	MESH:D000544
16914871	392	407	Down's syndrome	Disease	MESH:D004314
16914871	413	462	familial and sporadic cerebral amyloid angiopathy	Disease	MESH:D016657
16914871	464	467	CAA	Disease	MESH:D016657
16914871	527	534	AbetaPP	Gene	351
16914871	554	562	patients	Species	9606
16914871	635	640	Abeta	Gene	351
16914871	641	645	E22Q	ProteinMutation	tmVar:p|SUB|E|22|Q;HGVS:p.E22Q;VariantGroup:0;CorrespondingGene:351;CorrespondingSpecies:9606
16914871	704	711	AbetaPP	Gene	351
16914871	720	731	familial AD	Disease	MESH:D000544
16914871	733	736	FAD	Disease	MESH:D000544
16914871	801	806	Abeta	Gene	351
16914871	909	914	Abeta	Gene	351
16914871	931	938	AbetaPP	Gene	351
16914871	947	984	amyloid parenchymal plaque deposition	Disease	MESH:D058225
16914871	1072	1077	Abeta	Gene	351
16914871	1101	1106	Abeta	Gene	351
16914871	1233	1238	Abeta	Gene	351
16914871	1447	1455	toxicity	Disease	MESH:D064420
16914871	1515	1517	AD	Disease	MESH:D000544
16914871	1518	1526	patients	Species	9606
16914871	1554	1561	AbetaPP	Gene	351
16914871	1603	1608	Abeta	Gene	351
16914871	Association	MESH:D000544	351
16914871	Association	MESH:D016657	351
16914871	Association	MESH:D058225	351
16914871	Association	MESH:D064420	351
16914871	Association	MESH:D004314	351

